Outsourced Pharma White Papers

  1. Successful Techniques For Progressing Biotherapeutic Candidates From Late Discovery To The Clinic 1/26/2021

    Many initially promising biotherapeutic candidates fail due to lack of efficacy or safety, but there are also candidates that fail due to stability, aggregation, and other issues related to cell line or process issues. Prepare for a successful transition to bring your drug candidate from discovery to the clinic.

  2. Making The Medicine Go Down: Specialized Delivery Technologies 10/7/2020

    While most oral solid formulations are designed to release the drug immediately after swallowing, some products have been developed to provide a “controlled-release” of the drug products.

  3. Enabling Biologic Drug Delivery Of Volumes Beyond 1 mL 7/22/2020

    Delivery system manufacturers need to manage conflicting requirements and offer delivery solutions that balance performance, robustness, and usability while delivering higher volume or viscosity biologics.

  4. Embedding Your Drug Strategy Within A Solid Foundation For Success 3/24/2020

    This white paper looks at the set of trends influencing pharmaceutical development and manufacturing strategy today, and how these drivers are influencing new business models with outsourced partners. 

  5. From Research To Commercial: A Seamless Supply Of Oligonucleotides 4/24/2020

    This white paper discusses how to meet the seamless supply challenge by providing development, scale-up and synthesis capabilities of research to commercial quantities of customized oligonucleotides.

  6. It Hasn’t Been Easy For Pharma To Be Green 10/2/2020

    Most of the drugs coming to market today are acquired by large or mid-size pharma companies from small biotech companies. Partnering with a CDMO proficient in green chemistry and manufacturing can help a biotech create the most attractive drug package – one that includes a proven commercialization process minimizing toxic waste that pose safety concerns or require costly remediation.

  7. Navigating Regulatory And Development Milestones 9/17/2020

    This article addresses how early-stage biotherapeutic companies can avoid common pitfalls as they navigate the funding and regulatory processes to bring novel therapeutics from research to market.

  8. The Shift Toward US Pharmaceutical Manufacturing 9/1/2021

    The pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. Explore effective strategies to secure and de-risk pharmaceutical supply chains.

  9. Novel Platform Enables Creation Of ASD Solid Dosage Forms With High Drug Loadings 6/1/2020

    The prevalence of active compounds with low aqueous solubility exceeds 70% in drug pipelines, preventing the development of many compounds as effective medicines. A novel formulation platform makes it possible to meet the requirements for a successful high-loading spray-dried amorphous solid dispersion (ASD) dosage form, reducing tablet mass by nearly half to meet patient needs.

  10. Enabling Fast, Appropriate Drug Product Supply For Phase 1 Clinical Trials 10/30/2020

    Without the ability to move smoothly from lab concept to manufacture to delivery of GMP clinical supplies to patients, critical milestones could be missed, delaying funding commitments from investors.